Publication: Long-term effects of repeated oral dose of ivabradine on heart rate variability in dogs with asymptomatic degenerative mitral valve disease
Issued Date
2018-09-01
Resource Type
ISSN
01256491
Other identifier(s)
2-s2.0-85055148645
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Thai Journal of Veterinary Medicine. Vol.48, No.3 (2018), 423-431
Suggested Citation
Prapawadee Pirintr, Nakkawee Saengklub, Vudhiporn Limprasutr, Anusak Kijtawornrat Long-term effects of repeated oral dose of ivabradine on heart rate variability in dogs with asymptomatic degenerative mitral valve disease. Thai Journal of Veterinary Medicine. Vol.48, No.3 (2018), 423-431. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/47454
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Long-term effects of repeated oral dose of ivabradine on heart rate variability in dogs with asymptomatic degenerative mitral valve disease
Other Contributor(s)
Abstract
© 2018 Chulalongkorn University Printing House. All rights reserved. Degenerative mitral valve disease (DMVD) is the most common acquired cardiac disease in geriatric dogs leading to impaired cardiac autonomic activity and functions. This study aimed to evaluate the heart rate (HR), blood pressure (BP), myocardial oxygen consumption (MVO2) and heart rate variability (HRV) of dogs with DMVD stage B2 in response to long-term treatment with ivabradine, orally. Four beagles with naturally occurring DMVD stage B2 were instrumented with a 24-h Holter recorder to obtain electrocardiography and HRV, an oscillometric device to acquire blood pressure (BP), HR and myocardial oxygen consumption (MVO2) as assessed by rate-pressure product (RPP = HR x Systolic BP). Dogs were given ivabradine (1.0 mg/kg, twice daily, orally) for 3 months. Data were obtained at baseline and every 4 weeks for 12 weeks (M1 = 4 weeks, M2 = 8 weeks, and M3 = 12 weeks) after oral administration of ivabradine. The results revealed that chronic administration of ivabradine significantly decreased HR, BP, and RPP without adverse effects (P < 0.05). All indices of time- A nd frequency-domain of HRV at M3 were significantly increased when compared with baseline values (P < 0.05). The findings of this study imply that long-term treatment with ivabradine at a dose of 1.0 mg/kg twice daily in dogs with asymptomatic DMVD stage B2 decreased the HR, BP, MVO2 and improves HRV. This makes ivabradine potentially promising for management of elevated HR and impaired HRV in asymptomatic dogs with DMVD stage B2.